Afleveringen
-
Drs Ursula A. Matulonis and Akila N. Viswanathan discuss the role of radiation therapy in endometrial cancer, including staging, immunotherapy, and treatment disparities.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999853. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer Through Activation of Innate Immune Responses https://pubmed.ncbi.nlm.nih.gov/38169513/
Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/16330675/
Adjuvant Chemotherapy Plus Radiation for Locally Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31189035/
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone for Women With High-Risk Endometrial Cancer (PORTEC-3): Final Results of an International, Open-Label, Multicentre, Randomised, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/29449189/
Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/
FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/
Polymerase ɛ (POLE) Mutations in Endometrial Cancer: Clinical Outcomes and Implications for Lynch Syndrome Testing https://pubmed.ncbi.nlm.nih.gov/25224212/
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/37487144/
Risk Factors and Survival Impact Associated With Documentation of Radiation Therapy Refusal in Patients With Gynecologic Cancer https://pubmed.ncbi.nlm.nih.gov/37657506/
-
Drs Ursula A. Matulonis and Mansoor Mirza discuss immunotherapy trials, novel therapies such as CDK4/6 inhibitors and antibody-drug conjugates, and shared decision-making.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999852. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/
Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial https://pubmed.ncbi.nlm.nih.gov/37864337/
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) https://pubmed.ncbi.nlm.nih.gov/33078978/
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/37669480/
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/
-
Zijn er afleveringen die ontbreken?
-
Drs Ursula A. Matulonis and Bhavana Pothuri discuss solutions to address health disparities in the diagnosis and treatment of endometrial cancer.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999851. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview
Differential Trends in Rising Endometrial Cancer Incidence by Age, Race, and Ethnicity https://pubmed.ncbi.nlm.nih.gov/36625534/
Risk of Female-Specific Cancers According to Obesity and Menopausal Status in 2.7 Million Korean Women: Similar Trends Between Korean and Western Women https://pubmed.ncbi.nlm.nih.gov/34327357/
Uterine Cancer Is on the Rise, Especially Among Black Women https://www.nytimes.com/2022/06/17/health/uterine-cancer-black-women.html
New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines https://pubmed.ncbi.nlm.nih.gov/34073635/
A Molecular Perspective: Racial Disparities in Uterine Serous Carcinoma https://www.sciencedirect.com/science/article/abs/pii/S0090825822013105
Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy https://pubmed.ncbi.nlm.nih.gov/38529411/
Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/30741844/
Demographic Reporting and Language Exclusion in Gynecologic Oncology Clinical Trials https://pubmed.ncbi.nlm.nih.gov/37751830/
What's in It for Me?: A Value Assessment of Gynecologic Cancer Clinical Trials for Black Women https://pubmed.ncbi.nlm.nih.gov/36931101/
Just Ask! Increasing Diversity in Cancer Clinical Research https://courses.accc-cancer.org/products/just-ask-increasing-diversity-in-cancer-clinical-research#tab-product_tab_overview
Translational Research: Bridging the Gap Between Preclinical and Clinical Research https://pubmed.ncbi.nlm.nih.gov/36722550/
WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer Through Activation of Innate Immune Responses https://pubmed.ncbi.nlm.nih.gov/38169513/
ROCC/GOG-3043: A Randomized Non-inferiority Trial of Robotic Versus Open Radical Hysterectomy for Early-Stage Cervical Cancer https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS5605
Diverse Trials Act https://aaci-library.org/legislation-tracker/diverse-trials-act
-
Drs Ursula A. Matulonis and Joyce F. Liu discuss new therapeutics for patients with endometrial cancer, including ADCs, immunotherapy, and drugs targeting replication stress.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999850. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview
Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36291804/
Uterine Cancer https://emedicine.medscape.com/article/258148-overview
Integrated Genomic Characterization of Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/23636398/
Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability https://pubmed.ncbi.nlm.nih.gov/33182707/
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/
Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/
PDUFA VII: Fiscal Years 2023-2027 https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-vii-fiscal-years-2023-2027
NCCN Drugs & Biologics Compendium https://www.nccn.org/docs/default-source/clinical/drugs-and-biologics-compendium-user-guide.pdf
HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma https://pubmed.ncbi.nlm.nih.gov/37627113/
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu https://pubmed.ncbi.nlm.nih.gov/29584549/
Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33934848/
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma https://clinicaltrials.gov/study/NCT05256225
HER2 Amplification in p53-Mutated Endometrial Carcinomas https://pubmed.ncbi.nlm.nih.gov/36900227/
Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/33335423/
Application of NGS Molecular Classification in the Diagnosis of Endometrial Carcinoma: A Supplement to Traditional Pathological Diagnosis https://pubmed.ncbi.nlm.nih.gov/36341543/
FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/
The Role of Immunotherapy in Advanced and Recurrent MMR Deficient and Proficient Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/36493574/
Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35045221/
Phase 3, Randomized, Open-Label Study of Pembrolizumab Plus Lenvatinib Versus Chemotherapy for First-Line Treatment of Advanced or Recurrent Endometrial Cancer: ENGOT-en9/LEAP-001 https://pubmed.ncbi.nlm.nih.gov/34799418/
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://pubmed.ncbi.nlm.nih.gov/37870536/
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology https://pubmed.ncbi.nlm.nih.gov/27841667/
FDA Grants Accelerated Approval to Fam-trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
-
Drs Ursula A. Matulonis and Alexi A. Wright discuss survivorship issues in endometrial cancer including sexual dysfunction, mental health, fatigue, and peripheral neuropathy.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999849. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview
Cancer Survivorship Guidelines https://emedicine.medscape.com/article/2500027-overview
Patterns and Predictors of Cancer-Related Fatigue in Ovarian and Endometrial Cancers: 1-Year Longitudinal Study https://pubmed.ncbi.nlm.nih.gov/32436610/
Research Status of Internet-Delivered Cognitive Behavioral Therapy in Cancer Patients https://pubmed.ncbi.nlm.nih.gov/38073902/
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/28253393/
Pilot Randomized Trial of an Acceptance-Based Telehealth Intervention for Women With Ovarian Cancer and PARP Inhibitor-Related Fatigue https://pubmed.ncbi.nlm.nih.gov/37708581/
Improvements Following Multimodal Pelvic Floor Physical Therapy in Gynecological Cancer Survivors Suffering From Pain During Sexual Intercourse: Results From a One-Year Follow-Up Mixed-Method Study https://pubmed.ncbi.nlm.nih.gov/35077479/
Mismatch Repair Deficiency and Clinicopathological Characteristics in Endometrial Carcinoma: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/33845554/
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm
US Trends in Opioid Access Among Patients With Poor Prognosis Cancer Near the End-of-Life https://pubmed.ncbi.nlm.nih.gov/34292766/
Enhanced Recovery After Surgery (ERAS): A Perspective Review of Postoperative Pain Management Under ERAS Pathways and Its Role on Opioid Crisis in the United States https://pubmed.ncbi.nlm.nih.gov/31868759/
-
Drs Ursula A. Matulonis and Kathleen N. Moore discuss the different aspects of antibody-drug conjugates (ADCs) in endometrial cancer, medications that are currently available, and promising HER2 ADCs.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999848. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Uterine Neoplasms Version 2.2024 — March 6, 2024 https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors https://dailynews.ascopubs.org/do/destiny-pantumor-02-trastuzumab-deruxtecan-has-activity-against-range-her2-expressing
LBA34 - Trastuzumab Deruxtecan (T-DXd) for Pretreated Patients (pts) With HER2-Expressing Solid Tumors: Primary Analysis From the DESTINY-PanTumor02 (DP-02) Study https://oncologypro.esmo.org/meeting-resources/esmo-congress/trastuzumab-deruxtecan-t-dxd-for-pretreated-patients-pts-with-her2-expressing-solid-tumors-primary-analysis-from-the-destiny-pantumor02-dp-02
Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33934848/
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gy026?filter=nrg-gy026
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730032/
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology https://pubmed.ncbi.nlm.nih.gov/27841667/
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial https://pubmed.ncbi.nlm.nih.gov/36977309/
A Study of DB-1303 in Advanced/Metastatic Solid Tumors https://clinicaltrials.gov/study/NCT05150691
DNA Mismatch Repair Proteins: Scientific Update and Practical Guide https://pubmed.ncbi.nlm.nih.gov/33597222/
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) https://clinicaltrials.gov/study/NCT04209855
PRO1184 for Advanced Solid Tumors (PRO1184-001) https://www.clinicaltrials.gov/study/NCT05579366
A New Wave of Innovations Within the DNA Damage Response https://pubmed.ncbi.nlm.nih.gov/37679326/
Center for DNA Damage and Repair https://www.dana-farber.org/research/integrative-research/dna-damage-and-repair
The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions https://pubmed.ncbi.nlm.nih.gov/33806979/
Genomic Landscape of Endometrial Carcinomas of No Specific Molecular Profile https://pubmed.ncbi.nlm.nih.gov/35365770/
The Emerging Genomic Landscape of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/24170611/
